Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Updates for media on the latest products, offerings and developments across our business.
Jan 12, 2023
Catalent and Ethicann announced a development and license agreement to develop Ethicann’s clinical drug pipeline using Catalent’s proprietary Zydis® orally disintegrating tablet technology.
Jan 5, 2023
Catalent and Sarepta sign an agreement to manufacture delandistrogene moxeparvovec, Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy.
Dec 14, 2022
Catalent today announced a $12 million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City, Missouri.
Dec 8, 2022
The new facility will be one of the largest in the world with multi-product, segregated suites designed to support autologous and allogeneic cell therapy manufacturing.
Dec 1, 2022
The project has seen the site increase by approximately 30,000 square feet, which has allowed the installation of additional refrigerated and deep-frozen storage, and secondary packaging capabilities to be expanded.
Nov 3, 2022
The ADC candidates have been developed using Catalent’s proprietary SMARTag® technology.
Oct 20, 2022
Catalent today announced a $12 million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City, Missouri.
Sep 19, 2022
Karen will become a member of the Company’s Executive Leadership Team and serve as its principal accounting officer.
Sep 12, 2022
The investment will increase the site’s footprint by nearly 20% to 31,000 square feet, and allow the installation of 35 new freezers for ultra-low temperature (ULT) storage.
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
